Low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) levels are independently associated with atherosclerotic cardiovascular disease (ASCVD). However, the relationship between Lp(a) ...
Hypocholesterolemia involves having cholesterol levels that are too low. It cause health complications such as cardiovascular ...
Here, we reveal the role of Ras-related protein Rab-2A (Rab2A) in mediating LD-Golgi interactions, thereby contributing to very-low-density lipoprotein (VLDL) lipidation and secretion in hepatocytes.
Lipoprotein (a) is an independent risk factor for atherosclerotic cardiovascular disease. However, lipoprotein (a) testing remains variable and it is unclear what factors influence testing and if ...
The core of the lipoprotein, containing cholesterol ester and TG, is nonpolar and hydrophobic, and the outer layer of the lipoprotein particle (containing free cholesterol, phospholipid ...
Eli Lilly said a Phase 2 clinical trial for its treatment to inhibit lipoprotein(a) formation met its primary endpoint. Eli Lilly said the treatment, a once-daily pill called muvalaplin ...
The ALPACAR trial showed that among patients with ASCVD and elevated lipoprotein(a), zerlasiran reduces lipoprotein(a) by >80%. Patients with ASCVD and elevated lipoprotein(a) were randomized to ...
Definition, global prevalence, and significance of dyslipidaemias Phenotypically, dyslipidaemias are defined as disordered lipid and lipoprotein metabolism characterised by high concentrations of ...
The KRAKEN trial showed that among patients with high cardiovascular risk and elevated lipoprotein(a), muvalaplin reduces lipoprotein(a) levels. Patients with high cardiovascular risk and elevated ...
In addition, a number of ALLHAT participants (n=10,337) participated in a randomized, open-label trial designed to determine whether lowering low-density lipoprotein cholesterol with the HMG-CoA ...
When reading nutrition labels, be mindful of the serving size, calories, and sugar content of what you’re eating. Read food ...